Stimuli-sensitive protein delivery systems

Numerous recently developed therapies have highlighted the advantages of using proteins as therapeutics. However, in many protein delivery systems, the complicated carrier designs, low loading content, and off-targeting phenomenon have...

Download Full-text

Peptide and Protein Delivery Using New Drug Delivery Systems

Critical Reviews in Therapeutic Drug Carrier Systems ◽

10.1615/critrevtherdrugcarriersyst.2013006955 ◽

2013 ◽

Vol 30 (4) ◽

pp. 293-329 ◽

Cited By ~ 58

Author(s):

Ashish Jain ◽

Aviral Jain ◽

Arvind Gulbake ◽

Satish Shilpi ◽

Pooja Hurkat ◽

...

Keyword(s):

Drug Delivery ◽

Protein Delivery ◽

Drug Delivery Systems ◽

Delivery Systems ◽

New Drug

Download Full-text

Bone Morphogenetic Protein Delivery Systems

Spine ◽

10.1097/00007632-200208151-00005 ◽

2002 ◽

Vol 27 (Supplement) ◽

pp. S16-S23 ◽

Cited By ~ 150

Author(s):

Howard Seeherman ◽

John Wozney ◽

Rebecca Li

Keyword(s):

Bone Morphogenetic Protein ◽

Protein Delivery ◽

Delivery Systems ◽

Morphogenetic Protein

Download Full-text

Extracellular Vesicles as Natural Nanosized Delivery Systems for Small-Molecule Drugs and Genetic Material: Steps towards the Future Nanomedicines

Journal of Pharmacy & Pharmaceutical Sciences ◽

10.18433/j36w3x ◽

2015 ◽

Vol 18 (3) ◽

pp. 396 ◽

Cited By ~ 25

Author(s):

Mustafa Kotmakçı ◽

Vildan Bozok Çetintaş

Keyword(s):

Extracellular Vesicles ◽

Small Molecule ◽

Protein Delivery ◽

Drug Loading ◽

Genetic Material ◽

Delivery Systems ◽

Small Molecule Drugs ◽

The Common ◽

Therapeutic Protocols ◽

Targeting Ability

A new platform for drug, gene and peptide-protein delivery is emerging, under the common name of “extracellular vesicles”. Extracellular vesicles (EVs) are 30-1000 nm-sized cell-derived, liposome-like vesicles. Current research on EVs as nano-delivery systems for small-molecule drugs and genetic material, reveal that these tiny, biologically-derived vesicles carry a great potential to boost the efficacy of many therapeutic protocols. Several features of EVs; from efficacy to safety, from passive to active targeting ability, the opportunity to be biologically or chemically labelled, and most importantly, their eobiotic origin make them promising candidate for development of the next generation personalized nanomedicines. The aim of this article is to provide a view on the current research in which EVs are used as drug/genetic material delivery systems. Their application areas, drug loading and targeting strategies, and biodistribution properties are discussed.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Download Full-text